San Francisco Welcomes JPM24 with ADCs in High Demand

Licensing deals and ADCs drive biopharma deal flow in 2023

The biopharma industry experienced a tapering off in deal flow in 2023, but according to a new report from J.P. Morgan, the big companies in the industry still knew what they wanted. The report reveals that antibody-drug conjugates (ADCs) were the hot commodity driving the fourth-quarter spike in licensing deal proceeds, offering a glimmer of hope to an industry that had been battered by outside forces and grim financing prospects.